Markets INKT

MiNK Selected For ARPA-H Program To Advance Room-Temperature Cell Therapy

September 30, 2026 — 09:28 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Wednesday, MiNK Therapeutics (INKT) said its agenT-797 iNKT cell therapy platform was selected for an ARPA-H-funded initiative aimed at enabling room-temperature storage and transport of cell therapies.

The program is part of ARPA-H's four-year BioStabilization Systems (BoSS) initiative, which has committed up to $87 million to reduce reliance on cryogenic cold-chain infrastructure.

MiNK will participate in a team led by Draper developing technologies to stabilize living cell therapies at room temperature.

The team plans to use AI-assisted design and freeze-assisted droplet drying to optimize formulations and preserve cell function.

MiNK will contribute its allogeneic iNKT platform, cGMP manufacturing capabilities and cell-therapy development expertise to the program.

INKT shares closed on Tuesday at $12.26, up 1.24%.

In the Premarket trading, shares are up 3.89% at $12.74.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
INKT

Latest Articles
Data is currently not available